<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575818</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG4059-CL-101</org_study_id>
    <secondary_id>2020-000036-22</secondary_id>
    <nct_id>NCT04575818</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059</brief_title>
  <official_title>A First-in-human, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of GLPG4059 in Adult, Healthy, Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety, tolerability and pharmacokinetics&#xD;
      of GLPG4059 in healthy volunteers after single oral administrations of GLPG4059 (SAD),&#xD;
      compared to placebo (part 1). The effect of food (FE) (high-fat, high calorie) on the&#xD;
      pharmacokinetics and relative bioavailability (rBA) of GLPG4059 will be assessed (part 2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Development of compound has been stopped&#xD;
  </why_stopped>
  <start_date type="Actual">September 16, 2020</start_date>
  <completion_date type="Actual">April 8, 2021</completion_date>
  <primary_completion_date type="Actual">April 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1 (SAD) is randomized, double-blind, placebo-controlled; Part 2 (FE and rBA) is randomized, open-label.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events, and TEAEs leading to treatment discontinuations</measure>
    <time_frame>From screening through study completion, an average of 7 months</time_frame>
    <description>To evaluate the safety and tolerability of single ascending oral doses of GLPG4059, in adult, healthy, male subjects compared with placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GLPG4059</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the pharmacokinetics (PK) of single ascending oral doses of GLPG4059, in adult, healthy, male subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC) of GLPG4059</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the PK of single ascending oral doses of GLPG4059, in adult, healthy, male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2) of GLPG4059</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To evaluate the PK of single ascending oral doses of GLPG4059, in adult, healthy, male subjects</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLPG4059 SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses of GLPG4059 at up to 6 dose levels in ascending order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG4059 rBA/FE oral suspension fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG4059 in fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG4059 rBA/FE tablet fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG4059 in fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG4059 rBA/FE tablet fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG4059 in fasted state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG4059 oral suspension</intervention_name>
    <description>GLPG4059 for oral administration</description>
    <arm_group_label>GLPG4059 SAD</arm_group_label>
    <arm_group_label>GLPG4059 rBA/FE oral suspension fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral suspension</description>
    <arm_group_label>Placebo SAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG4059 tablet</intervention_name>
    <description>GLPG4059 for oral administration</description>
    <arm_group_label>GLPG4059 rBA/FE tablet fasted</arm_group_label>
    <arm_group_label>GLPG4059 rBA/FE tablet fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male between 18-54 years of age (extremes included), on the date of signing the&#xD;
             informed consent form (ICF).&#xD;
&#xD;
          -  A body mass index (BMI) between 18-30 kg/m2, inclusive.&#xD;
&#xD;
          -  Judged to be in good health by the investigator based upon the results of a medical&#xD;
             history, physical examination, vital signs, 12-lead ECG, and fasting clinical&#xD;
             laboratory safety tests, available at screening and prior to randomization. ECG and&#xD;
             vital signs parameters must be within the normal ranges. Bilirubin, aspartate&#xD;
             aminotransferase (AST), and alanine aminotransferase (ALT) must be no greater than&#xD;
             1.5x upper limit of normal (ULN). Fasting plasma glucose must be &lt;6.99 mmol/L, fasting&#xD;
             defined as no caloric intake for at least 8 hours and hemoglobin A1c (HbA1c) &lt;6.5% (48&#xD;
             mmol/mol). The test should be performed in a laboratory using a method that is&#xD;
             national glycohemoglobin standardization program (NGSP) certified and standardized to&#xD;
             the diabetes control and complications trial (DCCT) assay. Other clinical laboratory&#xD;
             safety test results must be within the reference ranges or test results that are&#xD;
             outside the reference ranges need to be considered not clinically significant in the&#xD;
             opinion of the investigator.&#xD;
&#xD;
        This list only contains the key inclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to Investigational Medicinal Product (IMP) ingredients or&#xD;
             history of a significant allergic reaction to IMP ingredients as determined by the&#xD;
             investigator.&#xD;
&#xD;
          -  Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus&#xD;
             (HCV) or history of hepatitis from any cause with the exception of hepatitis A that&#xD;
             was resolved at least 3 months prior to first dosing of the IMP.&#xD;
&#xD;
        This list only contains the key exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdalena Petkova, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <zip>9728</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

